Application of a validated prognostic plasma protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes: the Fremantle Diabetes Study Phase II.

Clinical Diabetes and Endocrinology Pub Date : 2024-10-10 DOI:10.1186/s40842-024-00191-8

Timothy M E Davis, Wendy A Davis, Scott D Bringans, James K C Lui, Tasha S C Lumbantobing, Kirsten E Peters, Richard J Lipscombe

{"title":"Application of a validated prognostic plasma protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes: the Fremantle Diabetes Study Phase II.","authors":"Timothy M E Davis, Wendy A Davis, Scott D Bringans, James K C Lui, Tasha S C Lumbantobing, Kirsten E Peters, Richard J Lipscombe","doi":"10.1186/s40842-024-00191-8","DOIUrl":null,"url":null,"abstract":"Background: There are scant data relating to prognostic biomarkers for chronic kidney disease (CKD) complicating type 1 diabetes. The aim of this study was to assess the performance of the plasma protein biomarker-based PromarkerD test developed and validated for predicting renal decline in type 2 diabetes in the context of type 1 diabetes.Methods: The baseline PromarkerD test score was determined in 91 community-based individuals (mean age 46.2 years, 56.5% males) with confirmed type 1 diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II. The performance of the PromarkerD test in predicting the risk of incident CKD (estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 in people without CKD at baseline) or an eGFR decline of ≥ 30% over the next four years was determined. The score can range from 0 to 100%, and is categorized as representing low (< 10%), moderate (10% to < 20%) or high (≥ 20%) risk.Results: The area under the receiver operating characteristic curve was 0.93 (95% confidence interval 0.87-0.99) for the composite renal endpoint, indicating strong predictive accuracy. The positive and negative predictive values at moderate (10% to < 20%) and high (≥ 20%) risk PromarkerD cut-offs were 46.7-50.0% and ≥ 92.0%, respectively.Conclusions: These preliminary data suggest that PromarkerD is at least as good a prognostic test for renal decline in type 1 as type 2 diabetes.","PeriodicalId":56339,"journal":{"name":"Clinical Diabetes and Endocrinology","volume":"10 1","pages":"30"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466018/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Diabetes and Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40842-024-00191-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There are scant data relating to prognostic biomarkers for chronic kidney disease (CKD) complicating type 1 diabetes. The aim of this study was to assess the performance of the plasma protein biomarker-based PromarkerD test developed and validated for predicting renal decline in type 2 diabetes in the context of type 1 diabetes.

Methods: The baseline PromarkerD test score was determined in 91 community-based individuals (mean age 46.2 years, 56.5% males) with confirmed type 1 diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II. The performance of the PromarkerD test in predicting the risk of incident CKD (estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m² in people without CKD at baseline) or an eGFR decline of ≥ 30% over the next four years was determined. The score can range from 0 to 100%, and is categorized as representing low (< 10%), moderate (10% to < 20%) or high (≥ 20%) risk.

Results: The area under the receiver operating characteristic curve was 0.93 (95% confidence interval 0.87-0.99) for the composite renal endpoint, indicating strong predictive accuracy. The positive and negative predictive values at moderate (10% to < 20%) and high (≥ 20%) risk PromarkerD cut-offs were 46.7-50.0% and ≥ 92.0%, respectively.

Conclusions: These preliminary data suggest that PromarkerD is at least as good a prognostic test for renal decline in type 1 as type 2 diabetes.

查看原文本刊更多论文

将针对 2 型糖尿病肾功能衰退的有效预后血浆蛋白生物标志物测试应用于 1 型糖尿病：弗里曼特尔糖尿病研究第二阶段。

背景：有关1型糖尿病并发慢性肾病（CKD）预后生物标志物的数据很少。本研究的目的是评估基于血浆蛋白生物标志物的 PromarkerD 测试的性能，该测试是为预测 2 型糖尿病肾功能衰退而开发和验证的，适用于 1 型糖尿病：方法：在弗里曼特尔糖尿病纵向观察研究第二阶段中，对 91 名社区确诊 1 型糖尿病患者（平均年龄 46.2 岁，56.5% 为男性）进行了 PromarkerD 测试基线得分测定。我们确定了 PromarkerD 测试在预测未来四年内发生慢性肾功能衰竭（基线时无慢性肾功能衰竭者的估计肾小球滤过率 (eGFR) 为 2）或 eGFR 下降≥ 30% 的风险方面的性能。得分范围从 0 到 100%，被归类为低分（结果：综合肾脏终点的接收者操作特征曲线下面积为 0.93（95% 置信区间为 0.87-0.99），表明预测准确性很高。阳性和阴性预测值处于中等水平（10% 到结论：这些初步数据表明，Promarker 预测值的准确性很高：这些初步数据表明，PromarkerD 至少与 1 型和 2 型糖尿病肾功能衰退的预后检测结果一样好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Diabetes and Endocrinology

自引率

0.00%

发文量

审稿时长

8 weeks

期刊介绍： Clinical Diabetes and Endocrinology is an open access journal publishing within the field of diabetes and endocrine disease. The journal aims to provide a widely available resource for people working within the field of diabetes and endocrinology, in order to improve the care of people affected by these conditions. The audience includes, but is not limited to, physicians, researchers, nurses, nutritionists, pharmacists, podiatrists, psychologists, epidemiologists, exercise physiologists and health care researchers. Research articles include patient-based research (clinical trials, clinical studies, and others), translational research (translation of basic science to clinical practice, translation of clinical practice to policy and others), as well as epidemiology and health care research. Clinical articles include case reports, case seminars, consensus statements, clinical practice guidelines and evidence-based medicine. Only articles considered to contribute new knowledge to the field will be considered for publication.